DermTech, Inc.

DermTech, Inc. (Nasdaq: DMTK) is a precision dermatology company that entered the public markets through a SPAC business combination in 2020, operating in the healthcare and medical diagnostics sector. The company develops non-invasive genomic testing technology for skin analysis, with its adhesive skin patch platform designed to support early detection of melanoma without traditional surgical biopsy. On May 9, 2023, DermTech filed a DEFA14A — additional definitive proxy materials — with the SEC, supplementing an active shareholder communications process. The filing reflects ongoing corporate governance activity at a company operating in a capital-intensive diagnostics market. For the complete filing history, SPAC transaction details, and real-time data coverage on DMTK, sign up for full access at SpacDesk.